Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 09:11 pm
Share
Y-mAbs Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 20.75 million compared to USD 10.8 million a year ago. Net loss was USD 6.3 million compared to USD 41.13 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.94 a year ago.
For the six months, revenue was USD 41 million compared to USD 21.28 million a year ago. Net loss was USD 12.69 million compared to USD 69.2 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 1.58 a year ago.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Y-MABS THERAPEUTICS, INC. 
